Barclays’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Barclays’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-32,097	Closed	-$130K	–	5473
2023 Q4	$130K	Buy	32,097 +24,265	+310%	+$74K	﹤0.01%	4565
2023 Q3	$21.1K	Sell	7,832 -533	-6%	-$2.09K	﹤0.01%	4167
2023 Q2	$78K	Sell	8,365 -4,628	-36%	-$45.6K	﹤0.01%	3656
2023 Q1	$115K	Buy	12,993 +4,089	+46%	+$40.1K	﹤0.01%	4101
2022 Q4	$44.3K	Buy	8,904 +3,844	+76%	+$22.5K	﹤0.01%	4593
2022 Q3	$29K	Sell	5,060 -132	-3%	-$933	﹤0.01%	3952
2022 Q2	$29K	Sell	5,192 -1,018	-16%	-$8.41K	﹤0.01%	4262
2022 Q1	$72K	Buy	+6,210	New	+$66.4K	﹤0.01%	3943

Barclays's THRX Position: Q1 2024 in Review

Barclays sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 32,097 shares — an estimated $130K sold.

Barclays first reported a position in THRX in Q1 2022 and held it in 8 quarters. The position peaked at $130K in Q4 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Barclays reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Barclays sold 32,097 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $130K.
Barclays first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
Barclays's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $130K in Q4 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.